Yahoo
NasdaqCM - Delayed Quote USD

DBV Technologies S.A. (DBVT)

16.00 -0.59 (-3.56%)
At close: June 8 at 4:00:00 PM EDT
16.30 +0.30 (+1.87%)
Pre-Market: 7:32:09 AM EDT
Trade DBVT on Coinbase
Chart Range Bar
Loading chart for DBVT
  • Previous Close 16.59
  • Open 16.75
  • Bid 17.33 x 100
  • Ask 16.00 x 100
  • Day's Range 15.84 - 16.78
  • 52 Week Range 8.50 - 26.18
  • Volume 178,468
  • Avg. Volume 245,358
  • Market Cap (intraday) 946.987M
  • Beta (5Y Monthly) -0.22
  • PE Ratio (TTM) --
  • EPS (TTM) -4.50
  • Earnings Date Jul 29, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 40.48

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

www.dbv-technologies.com

161

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 6/9/2026, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .

YTD Return

DBVT
16.71%
CAC 40 (^FCHI)
1.55%

1-Year Return

DBVT
75.25%
CAC 40 (^FCHI)
6.21%

3-Year Return

DBVT
321.05%
CAC 40 (^FCHI)
14.73%

5-Year Return

DBVT
40.85%
CAC 40 (^FCHI)
26.08%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 767.16k
Earnings -40.57M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-40M
-30M
-20M
-10M
0

Analyst Insights

View More

Analyst Price Targets

5.90 Low
40.48 Average
16.00 Current
54.85 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/4/2026
Analyst Guggenheim
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 51 -> 51

Statistics

View More

Valuation Measures

Annual
As of 6/5/2026
  • Market Cap

    1.03B

  • Enterprise Value

    809.57M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    4.72

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -66.36%

  • Return on Equity (ttm)

    -158.89%

  • Revenue (ttm)

    5.74M

  • Net Income Avi to Common (ttm)

    -167.45M

  • Diluted EPS (ttm)

    -4.50

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    229.2M

  • Total Debt/Equity (mrq)

    2.93%

  • Levered Free Cash Flow (ttm)

    -87.21M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

16.00 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: